A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 394 participants.

Also called NCT04936035

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 394 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04936035
  • EudraCT 2021-001248-82
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Canada, Puerto Rico, Ukraine, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04936035. Randomized; quadruple masking; primary purpose treatment. Start 2021-07-07 (actual); primary completion 2023-04-04 (actual). Results posted on 2024-12-27.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension
Acronym
KARDIA-1
Condition
Hypertension
Intervention (Drug)
Placebo
Intervention (Drug)
ALN-AGT01
Lead sponsor
Alnylam Pharmaceuticals (class: industry)

Record details

Record id
cardio:ct-nct04936035
Content hash
c785dc36c6981a3de13202f647cd094754d9d6627209803308a5672625b37d51